CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - thelancet.com
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …
被引用次数：137 相关文章

[引用][C] CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year …

JE Lancet, GL Uy, LF Newell, TL Lin, EK Ritchie… - The Lancet …, 2021 - cir.nii.ac.jp
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly
diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - profiles.wustl.edu
Background: Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - augusta.elsevierpure.com
Background: Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - ohsu.elsevierpure.com
Background: Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin… - The Lancet …, 2021 - europepmc.org
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

JE Lancet, GL Uy, LF Newell, TL Lin, EK Ritchie… - The Lancet …, 2021 - Elsevier
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …